Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space.

Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion protein agonist of ADCYAP1R1, a receptor involved in regulation of appetite and satiety, to treat non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and other gastrointestinal and liver diseases. The program is Salix's first for NASH or NAFLD...